Anlotinib exerts potent antileukemic activities in Ph chromosome negative and positive B-cell acute lymphoblastic leukemia via perturbation of PI3K/AKT/mTOR pathway-Reference-Cited by-同舟云学术

Anlotinib exerts potent antileukemic activities in Ph chromosome negative and positive B-cell acute lymphoblastic leukemia via perturbation of PI3K/AKT/mTOR pathway

Published:2022-11 Issue: Volume:25 Page:101516
ISSN:1936-5233
Container-title:Translational Oncology
language:en
Short-container-title:Translational Oncology

Author:

Chen Qiuling,Lai Qian^ORCID,Jiang Yuelong,Yao jingwei,Chen Qinwei,Zhang Li,Wang Caiyan,Zhou Yong,Deng Manman,Xu Bing

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference46 articles.

1. Acute lymphoblastic leukemia: a comprehensive review and 2017 update;Terwilliger;Blood Cancer J.,2017

2. Philadelphia chromosome-positive leukemia in the lymphoid lineage-similarities and differences with the myeloid lineage and specific vulnerabilities;Komorowski;Int. J. Mol. Sci.,2020

3. Outcomes for children and adolescents with cancer: challenges for the twenty-first century;Smith;J. Clin. Oncol.,2010

4. Relapsed childhood acute lymphoblastic leukaemia;Bhojwani;Lancet Oncol.,2013

5. Overall survival among older US adults with ALL remains low despite modest improvement since 1980: SEER analysis;Geyer;Blood,2017

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Aurora-A inhibitor synergistically enhances the inhibitory effect of anlotinib on hepatocellular carcinoma;Biochemical and Biophysical Research Communications;2024-01

2. Anlotinib suppresses the DNA damage response by disrupting SETD1A and inducing p53-dependent apoptosis in Transformed Follicular Lymphoma;International Journal of Medical Sciences;2024

3. Advancement of regulating cellular signaling pathways in NSCLC target therapy via nanodrug;Frontiers in Chemistry;2023-09-07

4. Knockdown of MEF2D inhibits the development and progression of B-cell acute lymphoblastic leukemia;Translational Cancer Research;2023-02

5. Research Progress of Anlotinib for Treating Gynecologic Malignancies;Advances in Clinical Medicine;2023